The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension
NCT ID: NCT00438945
Last Updated: 2008-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
18 participants
INTERVENTIONAL
2007-01-31
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eprosartan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index less or equal to 30 kg/m2.
* Women must use oral hormonal anticonceptive drugs, use intrauterine anticonceptive device, be sterilized / hysterectomized or be postmenopausal.
* Arterial hypertension, defined by 24 hour ambulatory blood pressure above 125 mmHg systolic or above 80 mmHg diastolic.
Exclusion Criteria
* History of stroke.
* Heart failure.
* Endocrine organ disease.
* Lung disease.
* Clinically significant abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine (under 200 µmol/L will be accepted), P-albumin, p-bilirubin, p-alaninaminotransferase, P-alkaline phosphatase, p-cholesterol and B-glucose.
* Clinically significant abnormal screening of the urine regarding: albumin and glucose (protein excretion below 0.5 g/L will be accepted).
* Renovascular hypertension.
* Malignant disease.
* Alcohol abuse.
* Usage of medical drugs besides antihypertensives or statins.
* Drug abuse.
* Pregnancy or breast feeding.
* Known intolerance or allergic to eprosartan or sodium nitroprusside.
* Blood donation within 1 month of the start of the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regional Hospital Holstebro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Medical Research, Holstebro Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erling B Pedersen, MD, professor
Role: STUDY_CHAIR
Department of Medical Research, Holstebro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Medical Research, Holstebro Hospital
Holstebro, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vase H, Lauridsen TG, Graffe CC, Pedersen EB. The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension. J Am Soc Hypertens. 2011 Sep-Oct;5(5):385-94. doi: 10.1016/j.jash.2011.03.007. Epub 2011 Jun 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MED.RES.HOS.2006.03.HV
Identifier Type: -
Identifier Source: org_study_id